Cipargamin

Cipargamin

Product development
-
Patient exploratory
Novartis
Asexual blood stages
Transmission reduction
Uncomplicated malaria treatments and resistance management (TPP-1)
Severe malaria treatment (TPP-1)
Product vision
  • Uncomplicated malaria treatment and resistance management
  • Severe malaria treatment
MOA
  • PfATP4 inhibitor
Key features
  • Novel mechanism of action for resistance management
  • Potentially simplified dosing schedule
  • Very rapid killing of parasites
  • Potential for transmission-blocking activity
Challenges

  • Identifying partner compound for oral and intravenous (i.v) development programme

  • Establish novel clinical endpoint for severe malaria
Status

  • Phase II oral malaria patient study and parenteral Good Laboratory Practice safety study completed

  • First-in-human study with intravenous (i.v.) formulation completed

  • Phase II monotherapy (i.v.) study in severe malaria patients ongoing
Next milestone

  • Complete phase II monotherapy (i.v.) study in severe malaria patients
Previously

  • NITD609, KAE609. Novartis in discovery partnership with MMV,  Wellcome Trust and the Swiss Tropical and Public Health Institute
Project Director
  • Yveline Angevelle